|Frequently asked questions|
Q. How does CoSolve work?
A. CoSolve is a virtual problem solving ecosystem where AstraZeneca publicly posts challenges looking for innovative solutions. An interested submitter will submit a brief description of their solution for review. Finalists will be selected to participate in the Challenge Week. The Challenge Week will bring together solvers for an intensive week to pitch their ideas and work with AstraZeneca scientists to transform their idea into a workplan. At the end of the challenge week, we will put a collaboration agreement in place with specified milestones and the project will begin.
Q. Are finalists required to participate in the Challenge Week if selected?
A. Yes, all finalists will have to agree to participate in the Challenge Week. You will also be asked to review and agree to the Heads of Terms which form the basis of the collaboration agreement which would be signed for winning solutions.
Q. Can I submit a solution even if I can’t enable it?
A. We are looking for great ideas and innovators who are able to enact the work. This is important because we are looking to break down the traditional barriers to collaboration and rapidly progress from idea to project.
Q. Can anyone submit a solution?
A. Yes, we are looking for anyone who has a great idea and wants to work with AstraZeneca to bring their idea to life provided they have the ability and freedom to operate that enables them to enact the solution in collaboration with AstraZeneca.
Q. How do I know what the terms of the collaboration agreement will be?
A. The heads of terms document (link) provides a high-level overview of the collaboration terms.
Q. How does the challenge week work?
A. The challenge week is a virtual engagement for the innovator to pitch a more in depth proposal of their idea and work up the solution with AstraZeneca scientists. Not all finalists will make it through to a final work plan.
Q. Who will provide funding?
A. AstraZeneca will provide funding for the projects to enable through the initial milestones. Continued partnership will be evaluated for projects on an individual basis (data driven).
Q. What is the anticipated duration of the collaboration?
A. We are looking for solutions that can be put into practice in a 12-18 month timeframe.
Q. Who owns the IP?
A. Full details for IP ownership will be found in the collaboration agreement. In general terms, both parties (AstraZeneca and the submitter) will each retain background IP and any IP generated as part of the collaboration will take into account the contributions from each party.
Q. How often are new challenges released?
A. New challenges are released quarterly. Each challenge round lasts approximately 12 weeks.
Q. Can I submit confidential information in my idea?
A. Initial submissions should contain only non-confidential information. Prior to the challenge week, if your idea/solution is shortlisted for detailed discussion, a confidential disclosure agreement (CDA) can be put in place on request for finalists to enable sharing confidential information.
Q. Who will be present during the challenge week?
A. Representatives from AstraZeneca will include the CoSolve team, relevant scientists from the therapy areas and product development teams related to the challenge as well as our business development colleagues who will put the agreement in place. The submitter shall bring with them all people relevant to the discussion including the innovator(s) developing the idea/workplan as well as the business development colleagues/tech transfer team.
Contact Us: firstname.lastname@example.org